Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: OCGN stock price vs ALNY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Needs ALNY P/S.
Implied fair value · at OCGN's multiple
Needs OCGN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OCGN FY 2025 (ended Dec 31, 2025) · ALNY FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
OCUGEN, INC. · implied price per share
Bear
-$0.05
Base
-$0.06
Bull
-$0.07
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
Bear
$24.50
Base
$28.82
Bull
$33.15
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-2.37x
3.75x
Net debt / EBITDA
Leverage against operating earnings
-0.15x
1.82x
Cash and equivalents
Liquid reserves on the balance sheet
$19.47M
$1.66B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
IOVANCE BIOTHERAPEUTICS, INC.
OCGN vs IOVA
bluebird bio, Inc.
OCGN vs BLUE
BioNTech SE
OCGN vs BNTX
Moderna, Inc.
OCGN vs MRNA
Legend Biotech Corp
OCGN vs LEGN
Arcturus Therapeutics Holdings Inc.
OCGN vs ARCT
Sarepta Therapeutics, Inc.
OCGN vs SRPT
VERTEX PHARMACEUTICALS INC / MA
OCGN vs VRTX
ACADIA PHARMACEUTICALS INC
OCGN vs ACAD
$28.79M
$2.96B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe OCGN can rapidly and durably improve revenue growth, margins, and financial quality from current distressed levels, then hold only for a speculative turnaround; otherwise, the data support reducing exposure because OCGN trades far above ALNY-implied value while fundamentals and quality are materially weaker than ALNY.
OCGN’s current price of $1.51 sits at the top end of its historical band and far above ALNY-implied price of $0.15, implying roughly 90% downside on the provided P/S basis. The gap is driven by OCGN’s extremely high sales multiple and tiny revenue base relative to ALNY, not by superior growth or profitability.
Supporting Metrics
